Friday, July 10, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Neurology & CNS R&D Pipeline

Alzheimer's, Parkinson's, epilepsy, MS, and CNS pipeline assets tracked by phase and sponsor.

Programs 675

Quick answer

Neurology & CNS: NovaPharmaNews indexes 675 neurology & cns clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Alzheimer's, Parkinson's, epilepsy, MS, and CNS pipeline assets tracked by phase and sponsor.

Top sponsors

Pipeline programs

Page 6 of 15

  1. AXS-05

    Axsome Therapeutics

    Treatment Resistant Depression

    phase 2 small molecule completed

    1 trial

  2. AXS-05 (dextromethorphan-bupropion)

    Axsome Therapeutics

    Treatment Resistant Depression

    phase 2 small molecule terminated

    1 trial

  3. Active Treatment- CT1812 100 mg

    COGNITION THERAPEUTICS INC

    Alzheimer Disease

    phase 2 small molecule completed

    1 trial

  4. Active drug: pimavanserin 17mg (2 strength tablets)

    Acadia Pharmaceuticals B.V.

    Parkinson Disease

    phase 2 small molecule completed

    1 trial

  5. Amiloride

    United Therapeutics Europe Ltd

    Secondary Progressive Multiple Sclerosis

    phase 2 small molecule completed

    1 trial

  6. Aplindore

    LIGAND PHARMACEUTICALS INC

    Early Stage Parkinson's Disease

    phase 2 small molecule completed

    1 trial

  7. Armodafinil

    Teva Pharma GmbH

    Bipolar I Depression

    phase 2 small molecule completed

    1 trial

  8. Atomoxetin STADA 40 mg Hartkapseln, GELATIN

    Pari Pharma GmbH

    Healthy subjects with no neurological or psychiatric disorders

    phase 2 small molecule active

    1 trial

  9. Azeliragon

    vTv Therapeutics

    Alzheimer Disease

    phase 2 small molecule terminated

    1 trial

  10. B-CIT and SPECT imaging

    United Therapeutics Europe Ltd

    Parkinson Disease

    phase 2 small molecule completed

    1 trial

  11. BHV-7000, BHV-7000

    Biohaven Bioscience Ireland Limited

    Refractory Focal Onset Epilepsy

    phase 2 small molecule active

    1 trial

  12. BHV7000-302

    Biohaven Bioscience Ireland Limited

    Refractory Focal Onset Epilepsy

    phase 2 small molecule active

    1 trial

  13. BIIB122 225 mg

    Denali Therapeutics

    Parkinson Disease

    phase 2 small molecule active

    1 trial

  14. BIIB122, Placebo to BIIB122

    Denali Therapeutics

    Parkinson’s disease

    phase 2 small molecule active

    1 trial

  15. BMB-101

    BRIGHT MINDS BIOSCIENCES INC.

    Absence Epilepsy

    phase 2 small molecule active

    1 trial

  16. BP42155

    Hoffmann-La Roche

    Alzheimer's disease

    phase 2 small molecule active

    1 trial

  17. BP44745

    Hoffmann-La Roche

    Alzheimer’s Disease

    phase 2 small molecule active

    1 trial

  18. BP46016

    Hoffmann-La Roche

    Progressive Forms of Multiple Sclerosis (PMS)

    phase 2 small molecule active

    1 trial

  19. Berubicin hydrochloride

    Rani Therapeutics Holdings

    central nervous system (CNS) lymphomas

    phase 2 small molecule active

    1 trial

  20. Bone marrow mesenchymal stem cells autologous

    Lxo Ireland Designated Activity Company

    Multiple Sclerosis

    phase 2 other completed

    1 trial

  21. Bupropion

    BRIGHT MINDS BIOSCIENCES INC.

    Schizophrenia and Disorders With Psychotic Features

    phase 2 small molecule completed

    1 trial

  22. CBD-ESPRIT

    The George Institute

    Remitted early phase schizophrenia

    phase 2 small molecule active

    1 trial

  23. CERE-110: Adeno-Associated Virus injection Surgery

    SANGAMO THERAPEUTICS, INC

    Alzheimer's Disease

    phase 2 small molecule completed

    1 trial

  24. CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN])

    SANGAMO THERAPEUTICS, INC

    Idiopathic Parkinson's Disease

    phase 2 small molecule completed

    1 trial

  25. CERE-120: Adeno-Associated Virus Delivery of Neurturin

    SANGAMO THERAPEUTICS, INC

    Idiopathic Parkinson's Disease

    phase 2 mab completed

    1 trial

  26. CET/PT

    BRIGHT MINDS BIOSCIENCES INC.

    Schizophrenia

    phase 2 other completed

    1 trial

  27. CGXV813B12201

    Novartis Pharmaceuticals

    Schizophrenia

    phase 2 small molecule active

    1 trial

  28. CN008-0003

    Bristol-Myers Squibb Australia Pty Ltd

    Early Alzheimer’s Disease

    phase 2 small molecule active

    1 trial

  29. CN45320

    Hoffmann-La Roche

    Multiple Sclerosis (MS)

    phase 2 small molecule active

    1 trial

  30. CNSA-001

    PTC THERAPEUTICS, INC.

    Gastroparesis

    phase 2 small molecule completed

    1 trial

  31. CO40778

    Hoffmann-La Roche

    Pediatric Solid tumors and primary central nervous system (CNS) tumors

    phase 2 small molecule active

    1 trial

  32. CT1812

    COGNITION THERAPEUTICS INC

    Alzheimer's Disease

    phase 2 small molecule completed

    1 trial

  33. CT1812

    COGNITION THERAPEUTICS INC

    Mild to Moderate Alzheimer's Disease

    phase 2 small molecule completed

    1 trial

  34. CT1812

    COGNITION THERAPEUTICS INC

    Alzheimer Disease

    phase 2 small molecule completed

    3 trials

  35. CT1812

    COGNITION THERAPEUTICS INC

    Early Alzheimer's Disease

    phase 2 small molecule active

    1 trial

  36. CVHB937A12201

    Novartis Pharmaceuticals

    Alzheimer’s disease

    phase 2 small molecule active

    1 trial

  37. CX-8998

    Jazz Pharmaceuticals Ireland Limited

    Epilepsy

    phase 2 small molecule completed

    1 trial

  38. CX-8998

    Jazz Pharmaceuticals Ireland Limited

    Parkinson's Disease

    phase 2 small molecule terminated

    1 trial

  39. CYTB323N12101

    Novartis Pharmaceuticals

    Relapsing Multiple Sclerosis

    phase 2 small molecule active

    1 trial

  40. CYTB323R12101

    Novartis Pharmaceuticals

    Non-active Progressive Multiple Sclerosis (PMS)

    phase 2 small molecule active

    1 trial

  41. Clonazepam

    Jazz Pharmaceuticals Ireland Limited

    Epilepsy

    phase 2 small molecule completed

    1 trial

  42. D20-P012

    Pari Pharma GmbH

    Alzheimer Disease

    phase 2 small molecule active

    1 trial

  43. D24-P003

    Pari Pharma GmbH

    Treatment-resistant depression

    phase 2 small molecule active

    1 trial

  44. DAAOI-P

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Parkinson's Disease With Dementia

    phase 2 small molecule completed

    1 trial

  45. DMTs + taurine

    The First People's Hospital of Lianyungang

    Multiple Sclerosis (MS) Relapsing Remitting

    phase 2 small molecule active

    1 trial

  46. DR220204

    Tour Hekla

    psychiatry

    phase 2 small molecule active

    1 trial

  47. Dexmedetomidine

    COGNITION THERAPEUTICS INC

    Alzheimer Disease

    phase 2 small molecule completed

    1 trial

  48. Diazepam Buccal Film

    Aquestive Therapeutics

    Epilepsy

    phase 2 small molecule completed

    2 trials

Frequently asked questions

How many neurology & cns pipeline programs are tracked?

675 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.